SCHEMBL2343409

SCHEMBL2343409

FC1CCN(c2nc3c(c(-c4ccc(Cl)cc4)n2)CCNCC3)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 16/20 0.57
HTR2A P28223 15/20 0.57
HTR2B P41595 14/20 0.57
HTR7 P34969 2/20 0.46
HTR6 P50406 2/20 0.46
HTR3A P46098 1/20 0.46
KDM4E B2RXH2 1/20 0.44
S1PR2 O95136 1/20 0.44
LMNA P02545 1/20 0.44
KMT2A Q03164 1/20 0.44
HIF1A Q16665 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HTR1D P28221 1/20 0.42
HTR1E P28566 1/20 0.42
POLB P06746 1/20 0.41
MAPK1 P28482 1/20 0.41
ATM Q13315 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CETP P11597 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2338980 0.88 HTR2C (0.58) HTR2CHTR2AHTR2BHTR7HTR6
SCHEMBL2340772 0.88 HTR2C (0.60) HTR2CHTR2AHTR2BHTR7HTR6
SCHEMBL2336470 0.88 HTR2C (0.43) HTR2CHTR2AHTR2BKDM4ES1PR2
SCHEMBL2339520 0.87 HTR2C (0.61) HTR2CHTR2AHTR2BHTR7HTR6
SCHEMBL2339041 0.86 HTR2C (0.46) HTR2CHTR2AHTR2BKDM4ES1PR2
SCHEMBL2341735 0.85 HTR2C (0.60) HTR2CHTR2AHTR2BHTR6KDM4E
SCHEMBL3379796 0.83 HTR2A (0.47) HTR2CHTR2AHTR2BKDM4EKMT2A
SCHEMBL12449411 0.81 HTR2C (0.38) HTR2CHTR2AHTR2BKDM4ES1PR2
SCHEMBL2341116 0.80 HTR2A (0.58) HTR2CHTR2AHTR2BHTR7HTR6
SCHEMBL2342835 0.78 HTR2A (0.59) HTR2CHTR2AHTR2BHTR7HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110207717-A1 2-AMINOPYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-08-25 US claimed
US-8829011-B2 2-aminopyrimidine compounds as serotonin receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2014-09-09 US disclosed
US-8829011-B2 2-aminopyrimidine compounds as serotonin receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2014-09-09 US disclosed
US-20110207717-A1 2-AMINOPYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-08-25 US disclosed
WO-2010053825-A1 2-AMINOPYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207717-A1 2-AMINOPYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS HTR2A, HTR6, HTR5A HTR2C 6/4885HTR2A 1/4885HTR2B 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.